Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey

Authors: Orsi, G., Di Marco, M., Cavaliere, A., Niger, M., Bozzarelli, S., Giordano, G., Noventa, S., Rapposelli, I.G., Garajova, I., Tortora, G., Rodriquenz, M.G., Bittoni, A., Penzo, E., De Lorenzo, S., Peretti, U., Paratore, C., Bernardini, I., Mosconi, S., Spallanzani, A., Macchini, M., Tamburini, E., Bencardino, K., Giommoni, E., Scartozzi, M., Forti, L., Valente, M.M., Militello, A.M., Cascinu, S., Milella, M., Reni, M.

Source: In ESMO Open October 2021 6(5)

Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort

Authors: Peretti, U., Cavaliere, A., Niger, M., Tortora, G., Di Marco, M.C., Rodriquenz, M.G., Centonze, F., Rapposelli, I.G., Giordano, G., De Vita, F., Stuppia, L., Avallone, A., Ratti, M., Paratore, C., Forti, L.G., Orsi, G., Valente, M.M., Gaule, M., Macchini, M., Carrera, P., Calzavara, S., Simbolo, M., Melisi, D., De Braud, F., Salvatore, L., De Lorenzo, S., Chiarazzo, C., Falconi, M., Cascinu, S., Milella, M., Reni, M.

Source: In ESMO Open February 2021 6(1)

Tubulin inhibitors in non-small cell lung cancer: looking back and forward

Authors: Ferrara, R., Pilotto, S., Peretti, U., Caccese, M., Kinspergher, S., Carbognin, L., Karachaliou, N., Rosell, R., Tortora, G., Bria, E.

Source: Expert opinion on pharmacotherapy. 17(8):1113-1129

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100106467848.0x000001&indx=1&recIds=ETOCvdc_100106467848.0x000001

Immune Checkpoint Inhibitors for Non-small-cell Lung Cancer: Does that Represent a `New Frontier'?

Authors: Pilotto, S., Kinspergher, S., Peretti, U., Calio, A., Carbognin, L., Ferrara, R., Brunelli, M., Chilosi, M., Tortora, G., Bria, E.

Source: ANTICANCER AGENTS IN MEDICINAL CHEMISTRY. 15(3):307-313

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN368241645&indx=1&recIds=ETOCRN368241645

PO-1225 Hypofractionated radiotherapy after induction chemotherapy for advanced pancreatic cancer

Authors: Passoni, P., Broggi, S., Slim, N., Longobardi, B., Mori, M., Peretti, U., Macchini, M., Orsi, G., Balzano, G., Castoldi, R., Falconi, M., Del Vecchio, A., Cattaneo, G.M., Fiorino, C., Cascinu, S., Reni, M., Di Muzio, N.G.

Source: Radiotherapy and oncology. 161(S1):S1013-S1014

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100141316327.0x000001&indx=1&recIds=ETOCvdc_100141316327.0x000001

Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials

Authors: Pilotto, S., Di Maio, M., Peretti, U., Kinspergher, S., Brunelli, M., Massari, F., Sperduti, I., Giannarelli, D., De Marinis, F., Tortora, G., Bria, E.

Source: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 90(2):135-145

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN350740531&indx=1&recIds=ETOCRN350740531

PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine

Authors: Pilotto, S., Peretti, U., Novello, S., Rossi, G., Milella, M., Giaj Levra, M., Ciuffreda, L., Massari, F., Brunelli, M., Tortora, G.

Source: EXPERT OPINION ON PHARMACOTHERAPY. 14(5):597-608

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN328619130&indx=1&recIds=ETOCRN328619130

ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations.

Authors: Peretti, U.¹, Ferrara, R.¹, Pilotto, S.¹ sara.pilotto.85@gmail.com, Kinspergher, S.¹, Caccese, M.¹, Santo, A.¹, Brunelli, M.², Caliò, A.², Carbognin, L.¹, Sperduti, I.³, Garassino, M.⁴, Chilosi, M.², Scarpa, A.^2,5, Tortora, G.¹, Bria, E.¹

Source: Respiratory Research. 8/25/2016, Vol. 17, p1-10. 10p. 1 Color Photograph, 3 Charts, 2 Graphs.

Subject Terms: *PROTEIN genetics, *LUNG cancer, *PROGNOSIS, *ANAPLASTIC lymphoma kinase, *TUMORS, *DATABASES, *DISEASE susceptibility, *GENES, *GENETICS, *LUNG tumors, *GENETIC mutation, *PNEUMONECTOMY, *SMOKING, *TIME, *TRANSFERASES, *PHENOTYPES, *FLUORESCENCE in situ hybridization, *TREATMENT effectiveness, *PROPORTIONAL hazards models, *RETROSPECTIVE studies, *DISEASE progression, *KAPLAN-Meier estimator, *GENOTYPES

Impact of pancreatic enzyme replacement therapy (PERT) on survival in patients affected by advanced pancreatic ductal adenocarcinoma (PDAC) undergoing first-line chemotherapy

Authors: Trestini, I., Carbognin, L., Peretti, U., Sperduti, I., Caldart, A., Melisi, D., Auriemma, A., Soldà, C., Tregnago, D., Avancini, A., Pilotto, S., Bria, E., Tortora, G., Reni, M., Milella, M.

Source: Pancreatology. 20(S1):S153-S153

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100117375920.0x000001&indx=1&recIds=ETOCvdc_100117375920.0x000001

1479P Exploring second-line therapy outcome in pancreatic ductal adenocarcinoma (PDAC) patients with germlineBRCA1-2 pathogenic variants (gBRCA1-2pv)

Authors: Orsi, G., Milella, M., Nappo, F., Di Marco, M., Niger, M., Bozzarelli, S., Rodriquenz, M.G., Noventa, S., Giordano, G., Rapposelli, I.G., Bernardini, I., Vasile, E., Macchini, M., Peretti, U., Valente, M.M., Paratore, C., Spallanzani, A., Scartozzi, M., Cascinu, S., Reni, M.

Source: In Annals of Oncology September 2021 32 Supplement 5:S1092-S1092

1856P Clinical relevance of pancreatic enzyme replacement therapy (PERT) in patients affected by advanced pancreatic ductal adenocarcinoma (PDAC) undergoing first-line chemotherapy

Authors: Peretti, U., Trestini, I., Carbognin, L., Sperduti, I., Caldart, A., Melisi, D., Auriemma, A., Soldà, C., Tregnago, D., Avancini, A., Pilotto, S., Bria, E., Tortora, G., Reni, M., Milella, M.

Source: In Annals of Oncology September 2020 31 Supplement 4:S1062-S1062

P-286 Exploring chemotherapy holiday in pancreatic cancer patients responding to upfront nab-paclitaxel-gemcitabine containing regimens

Authors: Macchini, M., Peretti, U., Orsi, G., Zanon, S., Valente, M., Mazza, E., Cascinu, S., Reni, M.

Source: In Annals of Oncology July 2020 31 Supplement 3:S183-S183

Detection of EGFR alterations in circulating tumor DNA of non-small cell lung cancer by digital PCR and Next Generation Sequencing
17th National Congress of Medical Oncology

Authors: Malpeli, G., Simbolo, M., Pilotto, S., Lawlor, R. T., Peretti, U.

Source: Annals of oncology. 26(SUPPLEMENT 6):vi-vi

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCCN602706288&indx=1&recIds=ETOCCN602706288

PD-004 - Time to CA19.9 nadir: a clue for defining treatment duration of primary chemotherapy in resectable PDAC

Authors: Peretti, U., Reni, M., Zanon, S., Macchini, M., Mazza, E., Balzano, G., Tamburrino, D., Arcidiacono, P., Massimo, F., Gianni, L.

Source: In Annals of Oncology July 2019 30 Supplement 4:iv111-iv111

Lung Adenocarcinoma Patient Refractory to Gefitinib and Responsive to Crizotinib, with Concurrent Rare Mutation of the Epidermal Growth Factor Receptor (L861Q) and Increased

Authors: Pilotto, S., Bria, E., Peretti, U.

Source: JOURNAL OF THORACIC ONCOLOGY. 8(12):e105-e106

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN343173556&indx=1&recIds=ETOCRN343173556

D3 - Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (paxg regimen) in metastatic pancreatic adenocarcinoma

Authors: Zanon, S., Pircher, C., Chiaravalle, M., Macchini, M., Peretti, U., Balzano, G., Passoni, P., Nicoletti, R., Arcidiacono, P.G., Pepe, G., Doglioni, C., Romi, S., Gritti, E., Falconi, M., Gianni, L., Reni, M.

Source: In Annals of Oncology October 2017 28 Supplement 6:vi44-vi45

739P - Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (PAXG regimen) in metastatic pancreatic adenocarcinoma

Authors: Reni, M., Zanon, S., Pircher, C., Chiaravalli, M., Macchini, M., Peretti, U., Mazza, E., Balzano, G., Passoni, P., Nicoletti, R., Arcidiacono, P.G., Pepe, G., Doglioni, C., Romi, S., Ceraulo, D., Falconi, M., Gianni, L.

Source: In Annals of Oncology September 2017 28 Supplement 5:v252-v252

H20 Detection of EGFR alterations in circulating tumor DNA of non-small cell lung cancer by digital PCR and Next Generation Sequencing

Authors: Malpeli, G., Simbolo, M., Pilotto, S., Lawlor, R. T., Peretti, U., Bonizzato, G., Kinspergher, S., Ferrara, R., Cantu', C., Caccese, M.

Source: ANNALS OF ONCOLOGY. 26(SUPP/6):vi-vi

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN372974344&indx=1&recIds=ETOCRN372974344

1182P - RICTOR/PI3K/mTOR as a clinically relevant driver of poor prognosis in squamous cell lung carcinoma (SqCLC): Preliminary results of prognostic outliers according to a validated clinicopathological model

Authors: Pilotto, S., Simbolo, M., Sperduti, I., Novello, S., Vicentini, C., Peretti, U., Pedron, S., Milella, M., Mafficini, A., Visca, P., Volante, M., Facciolo, F., Santo, A., Infante, M., Carbognin, L., Brunelli, M., Chilosi, M., Scarpa, A., Tortora, G., Bria, E.

Source: In Annals of Oncology 1 October 2016 27 Supplement 6:vi409-vi409

A13 - Potentially druggable molecular and immune-related pathways drive the prognosis of resected squamous cell lung carcinoma (R-SqCLC): preliminary results of prognostic outliers according to a clinicopathological model

Authors: Pilotto, S., Simbolo, M., Sperduti, I., Novello, S., Vicentini, C., Peretti, U., Pedron, S., Milella, M., Mafficini, A., Visca, P., Volante, M., Facciolo, F., Santo, A., Infante, M., Carbognin, L., Brunelli, M., Chilosi, M., Scarpa, A., Tortora, G., Bria, E.

Source: In Annals of Oncology September 2016 27 Supplement 4:iv7-iv7